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for understanding the biology and
improving the therapy of breast and other
cancers. Samanta et al. demonstrate that
insulin-like growth factor-2 mRNA-
binding protein 3 (IMP3) contributes to
TAZ activation in breast cancer stem cells
by stabilizing WNT5B mRNA and
facilitating alternative Wnt signaling.
IMP3 and WNT5B also function together
to promote the transcription of SLUG,
which is necessary for TAZ nuclear
localization and activation.
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SUMMARY
Insulin-like growth factor-2 mRNA-binding protein 3
(IMP3) is an oncofetal protein associated with many
aggressive cancers and implicated in the function
of breast cancer stem cells (CSCs). The mechanisms
involved, however, are poorly understood. We
observed that IMP3 facilitates the activation of TAZ,
a transcriptional co-activator of Hippo signaling
that is necessary for the function of breast CSCs.
The mechanism by which IMP3 activates TAZ
involves both mRNA stability and transcriptional
regulation. IMP3 stabilizes the mRNA of an alterna-
tive WNT ligand (WNT5B) indirectly by repressing
miR145-5p, which targets WNT5B, resulting in TAZ
activation by alternative WNT signaling. IMP3 also
facilitates the transcription of SLUG, which is
necessary for TAZ nuclear localization and activa-
tion, by a mechanism that is also mediated by
WNT5B. These results demonstrate that TAZ can
be regulated by an mRNA-binding protein and that
this regulation involves the integration of Hippo and
alternative WNT-signaling pathways.
INTRODUCTION
IMP3 (insulin-like growth factor-2 [IGF2] mRNA-binding protein
3) is a member of a family of IGF2 mRNA-binding proteins that
function in RNA stabilization, trafficking, and localization (Nielsen
et al., 1999). This protein has attracted considerable interest
because it exhibits the properties of an oncofetal protein, and
its expression correlates with the aggressive behavior of many
tumors (Degrauwe et al., 2016; Jiang et al., 2006; Walter et al.,
2009; Wei et al., 2017). In breast cancer, IMP3 is associated
with the highly aggressive triple-negative (TNBC) subtype (Wal-
ter et al., 2009). The challenge is to identify specific proteins
and functions that are regulated by IMP3 and to establish the
contribution of IMP3 to the distinguishing features of TNBC. In
this direction, we implicated IMP3 in the function of breast can-
cer stem cells (CSCs) (Samanta et al., 2016), which is relevant
because TNBCs contain a much higher frequency of CSCs
than other breast cancer subtypes and this population of
cells is thought to be responsible for their aggressive behavior
(Pece et al., 2010). These findings are consistent with other
studies on the contribution of IMP3 to CSCs (Degrauwe
et al., 2016).
IMP3 has the potential to impact the expression of a multitude
of proteins, a consideration that has been substantiated by indi-
vidual nucleotide resolution UV crosslinking and immunoprecip-
itation (iCLIP) studies (Conway et al., 2016; Palanichamy et al.,
2016). Based on this fact, there is a need to identify specific pro-
teins that are regulated by IMP3, which are also important for the
biology of TNBC. As an approach to this problem, we compared
themRNA expression profile of TNBC cells to the same cells that
had been depleted of IMP3. The results obtained revealed that
the expression of genes known to be regulated by the Hippo
effectors YAP and TAZ is influenced by IMP3. This observation
piqued our interest because TAZ, in particular, has been impli-
cated in TNBC and the function of breast CSCs (Cordenonsi
et al., 2011; Park et al., 2015). For this reason, we investigated
the hypothesis that IMP3 facilitates TAZ activation and pursued
the mechanism involved.
RESULTS
Causal Relationship between IMP3 and TAZ in Breast
Cancer
To discover novel IMP3 targets that impact the aggressive
behavior of TNBC, we performed RNA sequencing analysis
using a TNBC cell line (SUM-1315) that had been transfected
with either a control small hairpin RNA (shRNA) or shRNAs spe-
cific for IMP3 (see Tables S1 and S2 for a summary of results).
Analysis of the sequencing data using gene set enrichment anal-
ysis (GSEA) revealed a causal link between IMP3 and the expres-
sion of established TAZ and YAP target genes (CTGF, CYR61,
andDKK1) (Piccolo et al., 2014; Yu andGuan, 2013) (Figure S1A),
which we verified by qPCR (Figure 1A). To gain additional insight
into the relationship between IMP3 and YAP/TAZ in breast can-
cer, we analyzed gene expression profiles of 2,509 patients us-
ing cBioPortal (Cerami et al., 2012; Gao et al., 2013). A positive
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Figure 1. Causal Relationship of IMP3 and TAZ in TNBC
(A) RNA sequencing result showing decreased expression of CTGF, CYR61, and DKK1 upon IMP3 depletion.
(B–D) Control and IMP3-depleted SUM-1315, MDA-435, andMDA-231 cells were (B) fractionated and blotted for IMP3 (cytoplasmic) and TAZ (nuclear) (actin and
histone H3 were used as loading controls for cytoplasmic and nuclear proteins, respectively); (C) assessed for TAZ localization by immunofluorescence (the bar
graphs show the quantification of TAZ localization in either the nucleus only or in both cytoplasm and nucleus); and (D) assayed for TAZ target gene expression
by qPCR.
(E) Control and IMP3-depleted SUM-1315 cells were transfected with an empty vector (EV) or IMP3-expressing construct that is resistant to shIMP3-1 and
stained for TAZ by immunofluorescence, and TAZ localization was quantified. Total RNA isolated from the same cells was used to quantify CTGFmRNA by qPCR
(right bar graph). Scale bar, 1 mm.
(legend continued on next page)
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correlation between IMP3 and TAZ mRNA expression was
observed, and their expression was enriched in basal-like and
claudin-low subtypes of breast cancers, the majority of which
are TNBCs (Figures S1B and S1C) (Badve et al., 2011; Prat
et al., 2010). We substantiated this result by demonstrating
that IMP3 and TAZ co-localize in TNBC (Figure S1D). In contrast,
YAP and IMP3 mRNA expression did not correlate significantly,
and the expression of YAP is distributed across breast cancer
subtypes (Figures S1B and S1C). Moreover, nuclear localization
of TAZ is associated with TNBC (Dı´az-Martı´n et al., 2015), but
YAP nuclear localization does not correlate with any specific
subtype (Vlug et al., 2013; Yuan et al., 2008). For these reasons,
we focused our efforts on IMP3 and TAZ.
The hypothesis emerged from the foregoing data that
IMP3 contributes to TAZ activation in TNBC. Before testing, we
excluded the possibility that IMP3 affects TAZ indirectly by influ-
encing cell proliferation (Figure S1E). Since nuclear localization is
an indicator of TAZ activation, we compared TAZ localization in
control and IMP3-depleted cells using both sub-cellular fraction-
ation and immunofluorescence. IMP3 depletion caused a signif-
icant decrease in nuclear TAZ localization and a concomitant
increase in its cytoplasmic localization (Figures 1B and 1C).
Also, IMP3 depletion decreased the expression of TAZ target
genes significantly (Figures 1D and S1F).
Subsequently, we strengthened our conclusion that IMP3
facilitates TAZ activation. To control for the specificity of
IMP3 depletion, we expressed IMP3 in IMP3-depleted cells
using a construct that is resistant to shRNA, and we observed
that this construct was able to rescue TAZ nuclear localization,
as well as target gene expression (Figure 1E). CRISPR-
mediated IMP3 depletion in SUM-1315 cells also reduced
TAZ expression and the expression of TAZ target genes (Fig-
ure 1F). We also made use of SKBR3 cells, a non-TNBC cell
line, because they do not express IMP3 and express low levels
of TAZ (Figure 1G). Exogenous expression of IMP3 in these
cells increased nuclear TAZ expression, as well as TAZ target
genes (Figure 1G).
IMP3 Activation of TAZ Is Mediated by WNT5B
In the search for a mechanism by which IMP3 activates TAZ, a
possibility was that IMP3 increases TAZ mRNA stability. We
observed, however, that IMP3 depletion affected neither TAZ
mRNA expression nor its stability (Figure S2A). For this reason,
we were intrigued by our RNA sequencing data that the expres-
sion of WNT5B, an alternative WNT ligand (Park et al., 2015),
was diminished upon IMP3 depletion, because alternative Wnt
signaling has been implicated in TAZ activation (Park et al.,
2015).
The findings on WNT5B led us to hypothesize that the contri-
bution of IMP3 to TAZ activation is mediated byWNT5B and that
IMP3 regulates the expression of this non-canonical WNT ligand
directly. In pursuit of this hypothesis, we found that IMP3 deple-
tion in TNBC cell lines decreased WNT5B protein and mRNA
expression (Figures 2A and S2B) and exogenous expression
of IMP3 in SKBR3 cells increased WNT5B (Figure 2B), verifying
our RNA sequencing data. Moreover, depletion of WNT5B
reduced nuclear TAZ (Figure S2C), and its expression in IMP3-
depleted cells rescued TAZ target gene expression and nuclear
TAZ localization and it increased cytoplasmic TAZ (Figures 2C
and S2D). Importantly, we observed that IMP3 stabilizes
WNT5B mRNA (Figure S2E), providing a mechanism for how
IMP3 influences WNT5B expression.
We presumed that IMP3 binds directly to WNT5B mRNA, but
analysis of three independent published databases of IMP3-
boundmRNAs did not support this idea (Conway et al., 2016; En-
najdaoui et al., 2016; Palanichamy et al., 2016). We noticed,
however, that miR145-5p is elevated upon IMP3 depletion
(Figure 2D), which is relevant because this miR targets WNT5B
(Vlachos et al., 2015) and it is suppressed in TNBC (Sugita
et al., 2016). These observations suggested that IMP3 stabilizes
WNT5B mRNA by suppressing miR145-5p. Indeed, expression
of an anti-miR145-5p oligonucleotide in IMP3-depleted SUM-
1315 cells increased WNT5B mRNA, as well as TAZ target
gene expression (Figure 2E).
The mechanism by which alternative Wnt signaling activates
TAZ involves Rho GTPase activation and the consequent inhibi-
tion of large tumor suppressor kinase (LATS) activity (Park et al.,
2015; Yu et al., 2012). This is significant because LATS directly
phosphorylates TAZ at the serine 89 position and inhibits its nu-
clear localization and ability to regulate target gene expression
(Park et al., 2015). In support of our hypothesis that IMP3 acti-
vates TAZ by WNT5B signaling, we observed that LPA, a Rho
activator, rescued TAZ target gene expression in IMP3-depleted
cells (Figure 2F). Moreover, depletion of either IMP3 or WNT5B
increased LATS activity, as measured by phospho-LATS1
(Thr1079) and phospho-TAZ (Ser89), but it did not impact
LATS1 expression (Figure 2G).
A critical issue is whether IMP3 stabilization of WNT5B mRNA
and consequent TAZ activation are relevant to the function of this
RNA-binding protein. Previously, we reported that IMP3 contrib-
utes to mammosphere formation (Samanta et al., 2016), which is
also dependent on TAZ activation (Cordenonsi et al., 2011). For
this reason, we assessed whether WNT5B contributed to mam-
mosphere formation and whether it could rescue the ability of
IMP3-depleted cells to form mammospheres. Indeed, we found
that depletion of WNT5B decreased the mammosphere-forming
ability of SUM-1315 cells (Figure 2H, left bar graph) and
expression of WNT5B in IMP3-depleted cells rescued mammo-
sphere formation (Figure 2H, right bar graph). Moreover, shRNA-
mediated TAZ depletion decreased mammosphere formation
(Figure 2I) and exogenous expression of a constitutively active
TAZ (4SA-TAZ) (Lei et al., 2008) in either IMP3-depleted or
(F) IMP3 expression was depleted using IMP3-specific guide RNAs (gIMP3-1 and gIMP3-2) in SUM-1315 cells and assayed for expression of TAZ (immunoblots)
and its target genes (qPCR). A non-targeting gRNA (CT-gRNA) was used as the control.
(G) SKBR3 cells were transfected with an empty vector or a construct expressing IMP3 and fractionated and blotted for IMP3 (cytoplasmic) and TAZ (nuclear).
Total RNA extracted from the same cells was used to quantify TAZ target genes using qPCR. p% 0.05.
Relevant data are shown as ± SE.
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Figure 2. IMP3 Activation of TAZ Is Mediated by WNT5B
(A) Control and IMP3-depleted SUM-1315, MDA-435, and MDA-231 cells were blotted for WNT5B protein.
(B) SKBR3 cells were transiently transfected (48 hr) with an empty vector or IMP3-expressing construct (left immunoblot), and WNT5B mRNA was quantified by
qPCR using total RNA isolated from these cells (right bar graph).
(C) Control and IMP3-depleted SUM-1315 cells were transiently transfected with an empty vector (EV) or WNT5B-expressing construct for 48 hr. TAZ localization
was quantified in these cells by immunofluorescence (left bar graph). Total RNA was extracted and used to quantify the genes indicated in the right bar graph
by qPCR.
(D) RNA sequencing result showing increased expression of miR-145-5p upon IMP3 depletion.
(legend continued on next page)
2562 Cell Reports 23, 2559–2567, May 29, 2018
WNT5B-depleted cells increased mammosphere formation
(Figure 2J). Also, the expression of WNT5B, TAZ, and its target
genes is elevated in breast CSCs compared to non-CSCs (Al-
Hajj et al., 2003) (Figure S2F).
To exclude the possibility that IMP3 contributes to canonical
WNT signaling, we noted that the canonical WNT3A ligand is ex-
pressed at low levels in TNBC compared to other breast cancer
subtypes (Figure S2G). Also, we discovered that b-catenin is
primarily non-nuclear in TNBC cell lines and tumor specimens
and localized in cell membranes (Figure S2H). Moreover, IMP3
depletion did not impact b-catenin localization (data not shown).
There is also evidence that b-catenin is expressed at low levels in
TNBC (Shen et al., 2016).
Role of SLUG in IMP3 and WNT5B-Mediated TAZ
Activation
Previously, we reported that one mechanism by which IMP3
contributes to the aggressive behavior of TNBC and breast
CSCs is to regulate SLUG (Samanta et al., 2016). Moreover,
analysis of the cBioPortal database revealed that SLUG is ex-
pressed preferentially in TNBC and claudin-low tumors and
that it correlates with TAZ (Figure 3A). These findings are relevant
because SLUG has been shown to stabilize TAZ protein and
maintain its nuclear localization (Tang et al., 2016). For this
reason, we investigated a possible relationship between IMP3
regulation of WNT5B and SLUG. Initially, we found that SLUG
depletion in TNBC cell lines reduced nuclear TAZ and increased
TAZ cytoplasmic localization (Figures 3B and S3A) and it
decreased the expression of TAZ target genes (Figure 3C).
Also, exogenous expression of SLUG in SKBR3 cells increased
both nuclear TAZ and TAZ target genes (Figure 3D). More
definitive evidence was obtained by rescuing SLUG expression
in IMP3-depleted cells and observing a significant increase in
TAZ target genes (Figure 3E) and nuclear TAZ (Figure S3B). Inter-
estingly, although SLUG depletion increased TAZ phosphoryla-
tion, LATS1 phosphorylation remained unchanged (Figure 3F).
This observation verifies the report that SLUG promotes TAZ nu-
clear retention without affecting LATS kinase activity (Tang et al.,
2016). Moreover, treatment of SLUG-depleted cells with the Rho
activator LPA did not rescue TAZ target gene expression (Fig-
ure S3C), in agreement with the report that SLUG activation of
TAZ is independent of LATS kinase activity (Tang et al., 2016).
Although IMP3 regulates SLUG mRNA expression, it does not
impact the stability of SLUGmRNA (Figure S4A), suggesting that
it may contribute to the regulation of SLUG transcription. Trans-
fection of a luciferase reporter construct containing a 4-kb SLUG
promoter in control and IMP3-depleted cells revealed that
IMP3 depletion decreased luciferase activity significantly (Fig-
ure 4A). In an effort to integrate WNT5B into this mechanism,
we observed that WNT5B depletion reduced SLUG expression
significantly (Figure 4B), as well as TAZ target gene expression
(Figure 4C). In contrast, modulating SLUG expression had no
effect on WNT5B expression, indicating that SLUG functions
downstream of WNT5B (Figure S4B). Importantly, expression
of WNT5B in IMP3-depleted cells rescued SLUG mRNA (Fig-
ure 4D), as well as activity of the SLUG reporter construct
(Figure 4E). These data are strengthened by a positive correla-
tion between WNT5B and SLUG mRNA expression in patients
(Figure 4F).
DISCUSSION
This study contributes significantly to our understanding of
how IMP3 impacts the behavior of breast cancer cells, especially
cells from TNBCs. The fact that IMP3 is expressed preferentially
in TNBC among all the subtypes of breast cancer (Walter et al.,
2009) (Figure S1B) has suggested a causal role for this RNA-
binding protein in the aggressive behavior of these tumors,
which are characterized by a high frequency of CSCs (Pece
et al., 2010). Our implication of IMP3 in TAZ activation estab-
lishes this causal link because TAZ itself is expressed preferen-
tially in TNBC and it is important for breast CSCs, as well as
the aggressive behavior of poorly differentiated tumors (Corde-
nonsi et al., 2011). Moreover, our demonstration that the mech-
anism involves IMP3 regulation of a non-canonical WNT ligand
(WNT5B) reveals the importance of this signaling pathway and
its coordination with Hippo signaling in TNBC.
Although the importance of TAZ in breast and other cancers
has been affirmed (Zanconato et al., 2016), the mechanisms
that regulate its activation are less well understood. Our implica-
tion of IMP3 in TAZ activation provides one mechanism for
TNBC. Moreover, we discovered that this mechanism involves
the ability of IMP3 to regulate the stability of WNT5B mRNA
indirectly by repressing the expression of an miR that targets
WNT5B, enabling alternative WNT signaling. This observation
may relate to the interesting finding that IMP3 ribonucleoprotein
granules can function as safehouses that protect against
miR-mediated decay of target genes (Jønson et al., 2014). Our
(E) Control and IMP3-depleted SUM-1315 cells were transfected with either a control or anti-miR-145 oligonucleotide (20 nM) for 48 hr, and expression of WNT5B
and TAZ target genes mRNA was quantified by qPCR.
(F) Total RNA extracted from LPA- (1 mM, 2 hr) treated control and IMP3-depleted SUM-1315 cells was used to quantify TAZ target genes by qPCR. Blot inset
shows IMP3 depletion.
(G) Total cell extracts from control, IMP3-depleted, and WNT5B-depleted SUM-1315 and MDA-231 cells were blotted for pLATS1 (T1079), pTAZ (S89), and
WNT5B. pTAZ (S89) blots were obtained using a pYAP(S127) antibody that detects both pTAZ (S89) and pYAP.
(H) Control and WNT5B-depleted (shWNT5B-1 and shWNT5B-2) SUM-1315 cells were grown as mammospheres for 7 days, and the number of spheres was
quantified (left). Control and IMP3-depleted SUM-1315 cells were transiently transfected with an empty vector (EV) or a construct expressing WNT5B ligand,
grown as mammospheres for 7 days, and the number of spheres was quantified (right).
(I) Total extracts from control and TAZ-depleted (shTAZ-1 and shTAZ-2) SUM-1315 cells were blotted for TAZ (left blot). The same cells were grown as
mammospheres for 7 days and quantified (right graph).
(J) Control, IMP3, and WNT5B-depleted SUM-1315 cells were transfected with an empty vector or a vector expressing 4SA-TAZ, grown as mammospheres for
7 days, and quantified. p% 0.05.
Relevant data are shown as ± SE.
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findings are consistent with the observations that WNT5B
expression is enriched in TNBC compared to other WNT ligands
(Figure S2G) and that IMP3 is expressed specifically in TNBC
(Walter et al., 2009). Surprisingly, however, the expression of
WNT5A, another alternative WNT ligand, is very low in TNBC
and appears to be independent of IMP3 regulation. This obser-
vation is intriguing because WNT5A has been shown to enhance
the growth of mammary stem/progenitor cells (Kessenbrock
et al., 2017). In contrast, WNT5B represses the growth of these
cells (Kessenbrock et al., 2017), suggesting that the function
and expression of these alternative WNT ligands differ in mam-
mary gland biology and cancer.
Another important conclusion from our study is that IMP3 influ-
ences TAZ activation at multiple levels: WNT5B mRNA stability
and SLUG transcription. Previously, we had reported that IMP3
regulation of SLUG contributes to the behavior of TNBC cells,
but the mechanism involved escaped us and we were unable
to demonstrate that IMP3 affected SLUG mRNA stability (Sa-
manta et al., 2016). The data obtained here indicate that IMP3
regulates SLUG expression at the transcriptional level and that
this regulation is mediated by WNT5B by a mechanism that re-
mains to be determined. We also demonstrate that SLUG is
necessary for TAZ nuclear localization and activation, confirming
a previous study on osteogenesis (Tang et al., 2016). Similar to
Figure 3. SLUG Is Necessary for IMP3 Activation of TAZ
(A) Pie chart showing SLUGmRNA expression in breast cancer subtypes (PAM50 classification, cBioPortal). SLUG and TAZ expression was correlated using the
same database (right graph).
(B and C) SLUG expression was depleted using shRNAs (shSLUG-1 and shSLUG-2) in SUM-1315, MDA-435, and MDA-231 cells, and nuclear fractions were
blotted for SLUG and TAZ (B). The same cells were used to quantify TAZ target genes using qPCR (C).
(D) SKBR3 cells were transfected with an empty vector or a construct expressing SLUG, and nuclear fractions were blotted for SLUG and TAZ. Total RNA
extracted from the same cells was used to quantify TAZ target genes by qPCR.
(E) Control and IMP3-depleted SUM-1315 cells were transiently transfected with an empty vector (EV) or SLUG-expressing construct. Total RNA was extracted
and used to quantify TAZ target genes by qPCR.
(F) Total cell extracts from control and SLUG-depleted SUM-1315 and MDA-231 cells were blotted for pTAZ (S89) and LATS1 (T1079). p% 0.05.
Relevant data are shown as ± SE.
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IMP3 and WNT5B, SLUG is expressed preferentially in TNBC,
and it has been implicated in the genesis of these tumors (Guo
et al., 2012; Zhou et al., 2016). For this reason, mechanisms
that regulate its expression are critically important. There is evi-
dence, for example, that the SIRT deacetylase stabilizes SLUG
protein in this breast cancer subtype (Zhou et al., 2016). Our find-
ings suggest that SLUG expression can be regulated by multiple
mechanisms in TNBC, including transcription. Moreover, the
possibility that WNT5B contributes to the mechanism of SLUG
transcription suggests a novel function for this alternative WNT
ligand that may be distinct from the pathway bywhich it activates
TAZ by inhibiting LATS1/2 phosphorylation (Park et al., 2015).
Figure 4. WNT5B Mediates SLUG Transcription
(A) Control and IMP3-depleted HEK293FT and MDA-435 cells were transfected with a reporter construct bearing a 4-kb SLUG promoter upstream of firefly
luciferase, and they were assayed for luciferase activity (RLU) 24 hr post-transfection.
(B and C) Nuclear extracts from control and WNT5B-depleted SUM-1315 andMDA-231 cells were blotted for SLUG protein, and total RNA extracted from these
cells was used to quantify SLUG mRNA (B) and TAZ target genes by qPCR (C).
(D) Control and IMP3-depletedMDA-435 cells (shIMP3-1 and shIMP3-2) were transiently transfectedwith an empty vector orWNT5B-expressing construct. Total
RNA was extracted and used to quantify SLUG and WNT5B mRNA by qPCR.
(E) Control and IMP3-depleted HEK293FT cells were transfected with an empty vector (EV) or a construct expressing WNT5B. These cells were re-transfected
24 hr later with a SLUG-luciferase reporter construct and assayed for luciferase activity after another 24 hr.
(F) Expression of WNT5B and SLUG mRNA was correlated using cBioportal. The correlation coefficient (r) was estimated using Pearson’s correlation.
*p % 0.05.
Relevant data are shown as ± SE.
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EXPERIMENTAL PROCEDURES
RNA Sequencing Analysis
RNA sequencing analysis was performed using total RNA extracted from
control (shControl) and IMP3-depleted SUM-1315 cells. See the Supplemental
Experimental Procedures for details.
Biochemical Assays
Immunoblotting of whole-cell extracts, as well as cytoplasmic and nuclear
fractions, and qPCR were performed as described previously (Samanta
et al., 2016). Primers used for qPCR are listed in Table S3. Mammosphere
assays were performed as described previously (Samanta et al., 2016). For
the reporter assay, control or IMP3-depleted HEK293T cells were transfected
with a firefly luciferase reporter vector containing the SLUG promoter (4 kb)
(Chakrabarti et al., 2012) and assayed after 24 hr. A construct expressing
renilla luciferase was used as the transfection control. The relative light
unit (RLU) value was calculated as the ratio of firefly luciferase to renilla
luciferase activity (normalized luciferase activity). To measure mRNA stability,
control and IMP3-depleted SUM-1315 cells were treated with actinomycin-D
(5 mg/mL). Total RNAwas extracted and the expression of specificmRNAswas
quantified by qPCR.
Immunofluorescence Staining
Immunofluorescence staining of TAZ was performed as described previously
(Chang et al., 2015). The same protocol was used to stain b-catenin. Human
breast tumor sections were provided by Dr. Ashraf Khan (University of Massa-
chusetts Medical School).
Statistical Analysis
The data are shown as the ± SE. The p values (*) were determined using a
Student’s t test and p % 0.05 was considered significant. For correlation
studies, statistical significance was calculated by Pearson’s correlation.
DATA AND SOFTWARE AVAILABILITY
The accession number for the sequencing data reported in this paper is GEO:
GSE107564.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.04.113.
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